Association of Pharmaceutical Companies

Regimes of clinical trials data protection encourage companies to invest in pharmaceutical research in those countries where such ban is in effect. If the data exclusivity regime is violated in our country, confidence of foreign investors in the Russian market will be shattered.

Vadim Kukava, Executive Director InPharma

Pilot projects must be launched now. Only then we will be able to get a fully functioning compensation program in the country by 2019.

Vadim Kukava, Executive Director InPharma

The sooner patients get easy access to innovative treatments, the more lives we’ll be able to save every year.

Vadim Kukava, Executive Director InPharma

Pharmaceuticals is one of the most innovative industries that often spends billions of dollars and dozens of years to develop one new molecule

Vadim Kukava, Executive Director InPharma

Generally in our country diseases are treated only when they’re already in critical stages, even though everyone knows that early treatment is more effective and cheaper

Vadim Kukava, Executive Director InPharma

Pharmaceuticals is one of the industries that depend a lot on the protection of intellectual property because intellectual property plays a huge role in the business of innovative pharmaceutical companies.

Vadim Kukava, Executive Director InPharma

If everything is reduced to the issuance of mandatory licenses for medications, investor interest in the Russian market will collapse.

Vadim Kukava, Executive Director InPharma

Any cuts of the healthcare budget will have negative impact on society and the economy

Vadim Kukava, Executive Director InPharma

Additional budget funds will be required to include new effective drugs in the List of Vital and Essential Medicines, but it will reduce the incidence of diseases in the future and thus save the state money on treatment.

Vadim Kukava, Executive Director InPharma